Wearlinq, a San Francisco-based maker of a wireless clinical-grade wearable 6-lead EKG, has secured a $14 million Series A investment and $5 million in venture debt funding.  

“Today, I’m proud to share a major milestone for our team: we’ve raised a $14M Series A, led by AIX Ventures, with continued participation from our earliest supporters SpringTide Ventures, Berkeley Catalyst Fund, and Amino Capital, alongside other outstanding funds and a group of deeply experienced clinician and medtech operators,” said Konrad Morzkowski, cofounder and CEO of Wearlinq.

Heart disease is still the leading cause of death in the US and worldwide. Nearly 1 in 3 deaths are tied to it, and far too many are preventable with earlier detection, better monitoring, and timely treatment.

Related Pacemaker Smaller Than a Grain of Rice

The funding will allow Wearling to bring their technology to hundreds of thousands of patients in the near term, and many more in the years ahead, expanding access to high-quality cardiac monitoring that can meaningfully change outcomes.

Wearling’s eWave is a continuous, 6-lead wireless ECG cardiac monitor that interfaces with the wearer's phone and provides clinicians with reports in less than 48 hours along with real-time data. The wireless monitor can operate for over five days on a single charge, according to the manufacturer, reports MobiHealth News.

Although the business says it intends to expand into other indications in the future, the device can currently assist in the detection of arrhythmias.

“Even a 10% reduction in early heart disease death in the U.S. equates to over 100,000 lives saved,” explained Morzkowski. “There is no bigger mission for us, and this new funding gives us the ability to scale eWave nationally.”